A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

• Status: RECRUITING
• Trial end date: 2028-12-31

Summary

To find the recommended dose of eribulin that can be given in combination with irinotecan and temozolomide to treat relapsed and/or refractory solid tumors.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: eribulin; Irinotecan; Temozolomide